Anticancer activity and targeted delivery of metal-based drugs - Kryeziu, Kushtrim
61,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
31 °P sammeln
  • Broschiertes Buch

In this thesis, promising representatives of approved and novel metal-based drugs containing arsenic, ruthenium and platinum were analyzed for their anticancer activity. Strategies such as drug combinations, polymeric nanoformulations, and drug structure modifications were employed to increase their anticancer activity, overcome drug resistance, and reduce side effects. Summarizing, these studies suggest that metal-based drugs are promising anticancer therapeutics that can be further improved in their anticancer activity by structural modifications, combination with targeted therapeutics, as…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
In this thesis, promising representatives of approved and novel metal-based drugs containing arsenic, ruthenium and platinum were analyzed for their anticancer activity. Strategies such as drug combinations, polymeric nanoformulations, and drug structure modifications were employed to increase their anticancer activity, overcome drug resistance, and reduce side effects. Summarizing, these studies suggest that metal-based drugs are promising anticancer therapeutics that can be further improved in their anticancer activity by structural modifications, combination with targeted therapeutics, as well as application of biodegradable drug carriers for targeted delivery.
Autorenporträt
Kushtrim Kryeziu was born in Kapre, Kosovo in 1985. After graduation in genetics and microbiology at the University of Vienna he obtained his PhD at the Medical University of Vienna on malignant diseases. Kushtrim is a posdoctoral fellow at the Institute for Cancer Research in Oslo, Norway.